[go: up one dir, main page]

MX2023002347A - Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar. - Google Patents

Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar.

Info

Publication number
MX2023002347A
MX2023002347A MX2023002347A MX2023002347A MX2023002347A MX 2023002347 A MX2023002347 A MX 2023002347A MX 2023002347 A MX2023002347 A MX 2023002347A MX 2023002347 A MX2023002347 A MX 2023002347A MX 2023002347 A MX2023002347 A MX 2023002347A
Authority
MX
Mexico
Prior art keywords
fenretinide
pulmonary fibrosis
analogue
treat pulmonary
administration
Prior art date
Application number
MX2023002347A
Other languages
English (en)
Inventor
Radu Pislariu
Irenej Kianicka
Original Assignee
Laurent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurent Pharmaceuticals Inc filed Critical Laurent Pharmaceuticals Inc
Publication of MX2023002347A publication Critical patent/MX2023002347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para prevenir y/o retardar la progresión de y/o tratar la fibrosis pulmonar que comprende la administración de una cantidad terapéuticamente eficaz de fenretinida, análogo de fenretinida o sal farmacéuticamente aceptable del mismo.
MX2023002347A 2020-08-25 2021-08-19 Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar. MX2023002347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063069881P 2020-08-25 2020-08-25
PCT/CA2021/051148 WO2022040782A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Publications (1)

Publication Number Publication Date
MX2023002347A true MX2023002347A (es) 2023-04-20

Family

ID=80352354

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002347A MX2023002347A (es) 2020-08-25 2021-08-19 Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar.

Country Status (10)

Country Link
US (1) US20230310352A1 (es)
EP (1) EP4203931A4 (es)
JP (1) JP2023539847A (es)
KR (1) KR20230079054A (es)
CN (1) CN116437904A (es)
AU (1) AU2021329999A1 (es)
BR (1) BR112023003481A2 (es)
CA (1) CA3128648A1 (es)
MX (1) MX2023002347A (es)
WO (1) WO2022040782A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127164A2 (en) * 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Also Published As

Publication number Publication date
EP4203931A4 (en) 2024-11-13
EP4203931A1 (en) 2023-07-05
US20230310352A1 (en) 2023-10-05
BR112023003481A2 (pt) 2023-05-09
KR20230079054A (ko) 2023-06-05
WO2022040782A1 (en) 2022-03-03
AU2021329999A1 (en) 2023-03-23
CN116437904A (zh) 2023-07-14
JP2023539847A (ja) 2023-09-20
CA3128648A1 (en) 2022-02-25

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
ZA202102628B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
SA522441741B1 (ar) مركبات 2-أوكسو إيميدازوليدين -4- nav1.8 كربوكساميد كمثبطات لـ
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
PH12021552020A1 (en) Pharmaceutical formulations
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2022003845A (es) Tratamientos cognitivos medicinales.
ZA202308388B (en) Nasal compositions comprising alcaftadine
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2023002347A (es) Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar.
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MY205171A (en) Methods of treatment of hypertriglyceridemia
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CA3156118A1 (en) Intranasal pharmaceutical compositions of cyclobenzaprine
MX2024000081A (es) Derivados de cannabicromeno y métodos para fabricar y usar los mismos.
MY199846A (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
MX2022012707A (es) Metodos de tratamiento del sindrome respiratorio agudo grave.
WO2021007329A3 (en) Treatment of pulmonary fibrosis using inhibitors of neu1 sialidase